The Aspen Group (“Aspen”) is pleased to announce that Aspen Global Incorporated (“Aspen Global”), a wholly owned subsidiary of Aspen Holdings, has reached agreement with GlaxoSmithKline plc (“GSK”) for the acquisition of a portfolio of 25 established pharmaceutical products (“the Products”) which are distributed in Australia (“the Transaction”). The Transaction consideration is GBP 172 million… Continue reading Aspen Global acquires Australian product portfolio for R2.2 billion
Aspen will be in a closed period from 1 January 2025 until the publication of the Interim Results on the JSE SENS platform on 3 March 2025.
